Golfman, the synDNA candidate numbers that I used were just for the US market derived from some stats pulled from the FDA site along with a few guestimates. The world market could increase the eventual demand but I would not expect it to change the timing. I’m not sure other countries are any further along with approved DNA medicine and I’m also not sure cygx would have an easy in anywhere else even if they were further along. International drug approval requirements have generally been getting more stringent and dealing with import/export regulation would probably add some time to any international sales as well.
Long term getting into the world market should be a good thing. If the cost of synDNA advantage proves out in production, it may be sought out so that these new medicines can be brought to market at more affordable prices in less affluent countries. I would expect when that happens cygx would license the technology to a company that is already established in the interested company’s host country and minimize as much of the international trade regulations as possible. Short-term it still looks like this material will be used primarily in testing which will consist of a lot of small contracts and dealing with a bunch of individual sales in the US will probably keep the yet-to-be-announced sales team busy. The only short-term opportunity that I can see from the international market would be to license the technology to someone who is interested in pursuing sales to this test market but that has to be approached with caution. I’m not sure what international protection cygx has applied for at this point and as others have pointed out, in some places that protection doesn’t mean much anyway. In many countries it’s now “seller beware”.
Just some thoughts.
Market Data 
Markets 
AI
